Transitioning novel peptide hits into lead compounds

Developing novel peptide hits into lead compounds can be challenging and requires a modified approach compared to small molecules. When screening for hits on difficult drug targets such as orphan G-protein coupled receptors (GPCRs) or ion channels it is often necessary to go outside of the Lipinski rule of five. These compounds are in libraries which could include natural products, peptides, fragments etc. Finding the hit is the first step, and this then may be used as a tool to rescreen small molecules libraries with better confidence. But often this new hit needs to be investigated as potential lead material to progress the project from a potentially stalled situation. Unlike synthetic compound libraries, natural product hits need to be identified and then characterised as the actual molecule is often unknown. Peptide libraries come from a range of sources and they all have limitations and benefits. Venom peptides are often inherently stable due to cysteine knots whereas other peptides may not be. This article will take on the challenges of the hit-to-lead journey with these non-standard hits.

Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001 Mar;46(1–3):3–26.
Doak BC, Over B, Giordanetto F, Kihlberg J. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. Chem Biol. 2014 Sep;21(9):1115–42.
Goodwin D, Simerska P, Toth I. Peptides as therapeutics with enhanced bioactivity. Curr Med Chem. 2012;19(26):4451–61.
Henke MT, Kelleher NL. Modern mass spectrometry for synthetic biology and structure-based discovery of natural products. Nat Prod Rep. 2016 Aug;33(8):942–50.
Eustache S, Leprince J, Tuffery P. Progress with peptide scanning to study structure-activity relationships: the implications for drug discovery. Expert Opin Drug Discov. 2016 Aug;11(8):771–84.
Shcherbatko A, Rossi A, Foletti D, Zhu G, Bogin O, Galindo Casas M, et al. Engineering Highly Potent and Selective Microproteins against Nav1.7 Sodium Channel for Treatment of Pain. J Biol Chem. 2016 Jul;291(27):13974–86.
Diochot S, Baron A, Salinas M, Douguet D, Scarzello S, Dabert-Gay A, et al. Black mamba venom peptides target acid-sensing ion channels to abolish pain. Nature. 2012;490:552–7.
Harrington RA. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol. 1997 Aug;80(4A):34B–38B.
Gan ZR, Gould RJ, Jacobs JW, Friedman PA, Polokoff MA. Echistatin. A potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus. J Biol Chem. 1988 Dec;263(36):19827–32.
Safavi-Hemami H, Brogan SE, Olivera BM. Pain therapeutics from cone snail venoms: From Ziconotide to novel non- opioid pathways. J Proteomics. 2019 Jan;190:12–20.
Furman BL. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent. Toxicon. 2012 Mar;59(4):464–71.
Pennington M, Czerwinski A, Norton R. Peptide therapeutics from venom: Current status and potential. Bioorg Med Chem. 2017.
Ma L, Chin YKY, Dekan Z, Herzig V, Chow CY, Heighway J, et al. Novel venom-derived inhibitors of the human EAG channel, a putative antiepileptic drug target. Biochem Pharmacol. 2018 Aug;158:60–72.
Zhang Y, Peng D, Huang B, Yang Q, Zhang Q, Chen M, et al. Discovery of a Novel Nav1.7 Inhibitor From Cyriopagopus albostriatus Venom With Potent Analgesic Efficacy. Front Pharmacol. 2018;9:1158.
Wang CK, Craik DJ. Cyclic peptide oral bioavailability: Lessons from the past. Biopolymers. 2016 Nov; 106(6):901–9.
Whalley ET, Hanson WL, Stewart JM, Gera L. Oral activity of peptide bradykinin antagonists following intragastric administration in the rat. Can J Physiol Pharmacol. 1997 Jun;75(6):629–32.
Hardy MC, Daly NL, Mobli M, Morales RA V, King GF. Isolation of an orally active insecticidal toxin from the venom of an Australian tarantula. PLoS One. 2013;8(9):e73136.
Renukuntla. Approaches for Enhancing Oral Bioavailability of Peptides and Proteins. 2014;447(0):75–93.